Fibrinolytic Therapy for Progressive Systemic Sclerosis and Tissue Fibrinolytic Activity in Affected Skin

Abstract

In our present study, impairment of tissue fibrinolytic activity was observed in the affected skin of patients with progressive systemic sclerosis (PSS) by fibrinolytic autography. We treated PSS with a fibrinolytic agent, urokinase, based on the idea that the impairment of tissue fibrinolytic activity is implicated in the development of PSS. Two patients with PSS have responded favorably well to administration of Urokinase.